Table 3. Crude and adjusted rates and hazard ratios for mortality and for loss to follow-up by time to ART initiation.
| Time to ART initiation | Outcome | PY/100 | Rate/100py | 95% CI | cHRa | 95%CI | p-valueb | aHRc | 95%CI | p-valuec | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deaths (N=109) | ||||||||||||||
| 0-≤7d | 30 | 4.04 | 7.43 | 5.20 | 10.63 | 1.89 | 1.00 | 3.57 | 1.59 | 0.83 | 3.04 | |||
| >7-≤14d | 14 | 3.83 | 3.65 | 2.16 | 6.17 | 1 | 0.316 | 1 | <0.398 | |||||
| >14d-≤1mo | 19 | 4.32 | 4.39 | 2.80 | 6.88 | 1.37 | 0.69 | 2.74 | 1.19 | 0.59 | 2.40 | |||
| >1mo-≤2mo | 13 | 2.40 | 5.39 | 3.13 | 9.29 | 1.96 | 0.92 | 4.26 | 1.56 | 0.72 | 3.41 | |||
| >2mo | 8 | 2.80 | 2.85 | 1.43 | 5.70 | 1.59 | 0.65 | 3.90 | 1.08 | 0.44 | 2.71 | |||
| Prior to initiation | 25 | 2.55 | 9.81 | 6.63 | 14.53 | 1.23 | 0.61 | 2.47 | 0.94 | 0.46 | 1.92 | |||
| LTFU (N=226) | ||||||||||||||
| 0-≤7d | 32 | 4.04 | 7.93 | 5.61 | 11.21 | 0.96 | 0.59 | 1.57 | 1.02 | 0.62 | 1.67 | |||
| >7-≤14d | 32 | 3.83 | 8.35 | 5.91 | 11.81 | 1 | <0.04 | 1 | <0.04 | |||||
| >14d-≤1mo | 36 | 4.33 | 8.31 | 6.00 | 11.53 | 0.99 | 0.61 | 1.60 | 1.07 | 0.66 | 1.73 | |||
| >1mo-≤2mo | 13 | 2.41 | 5.40 | 3.13 | 9.30 | 0.78 | 0.41 | 1.48 | 0.85 | 0.44 | 1.64 | |||
| >2mo | 16 | 2.80 | 5.71 | 3.50 | 9.32 | 0.92 | 0.50 | 1.71 | 0.97 | 0.52 | 1.81 | |||
| Prior to initiation | 97 | 2.55 | 38.08 | 31.21 | 46.47 | 3.77 | 2.49 | 5.69 | 3.96 | 2.60 | 6.04 | |||
a
From Cox regression.
b
From LRT.
c
From Cox regression adjusted for sex, age, WHO stage, and calendar year of establishing ART eligibility.
aHR: Adjusted hazard ratio. ART: Antiretroviral therapy. cHR: Crude hazard ratio. d: Days. LTFU: Loss to follow-up. LRT: Likelihood ratio test mo: Month. PY: Person-year. WHO: World Health Organization. 95%CI: 95% confidence interval.